- Serine Endopeptidases
- Accession Number
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Drug Drug Description Alteplase A recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Urokinase A low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines. Reteplase A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Anistreplase A form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Tenecteplase A modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli. Coagulation factor VIIa Recombinant Human A form of recombinant human coagulation Factor VII used to treat hemophilia A and B. Streptokinase A purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Ancrod An anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country. Fibrinolysin Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas. Lanoteplase Investigated for use/treatment in myocardial infarction. Amediplase Investigated for use/treatment in myocardial infarction and thrombosis. Ocriplasmin A proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula. Batroxobin No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously. Chymotrypsin No therapeutic indications. Trypsin Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide... Thrombin A coagulation factor used to stop bleeding during surgery. Rusalatide acetate Chrysalin has been used in trials studying the treatment of Radius Fracture. Vonapanitase Vonapanitase is under investigation for the treatment of Chronic Kidney Disease. Vatreptacog alfa Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors. Monteplase Monteplase has been used in trials studying the treatment of Pulmonary Embolism. Kallidinogenase Not Annotated Saruplase Not Annotated Andexanet alfa A recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban. Sutilain Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular... Nattokinase Nattokinase is under investigation in clinical trial NCT00749801 (Efficacy and Safety of Geneferm Nattokinase). Thrombin alfa A platelet activating factor used to treat minor bleeding. Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Lactoferrin Lactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
- Drugs & Drug Targets